PRESS RELEASE: Can 2020 Push Hospitals From Good To Great?
The new Lown Institute Hospitals Index assesses civic leadership, value, and outcomes at US Hospitals. More
The new Lown Institute Hospitals Index assesses civic leadership, value, and outcomes at US Hospitals. More
If we want to start holding hospitals more accountable for improving their performance, however, we first need a reliable set of metrics to hold them accountable to. Unfortunately, those metrics don’t exist—not in government or the private sector. More
A new STAT analysis shows the effort to study treatments has been marked by disorder and chaos, with huge financial resources wasted. More
"At a time when communities are relying on them like never before, hospitals must rethink what it means to be great," said Vikas Saini, M.D., president of the Lown Institute. "COVID-19 highlights how hospitals are essential community partners for anyone in need. To be great, however, a hospital cannot only provide care that's high in quality. It must also deliver value and advance equality." More
Despite the ongoing coronavirus pandemic, hospitals are closing. Hospitals should serve the public, not owners' pocketbooks. More
Online registration, a drive through nasal swab and a short phone call. Then my insurance company was billed $1,844. More
In New York City’s poor neighborhoods, some patients have languished in understaffed hospitals, with substandard equipment. It was a different story in Manhattan’s private medical centers. More
Carmen Quintero couldn't get a coronavirus test but ended up with a huge bill for trying to. She also was told to self-isolate and had no choice but to use vacation time to stay home from work. More
The Lown Hospitals Index is a new kind of hospital ranking, one that takes into account the full breadth of what hospitals do. More
The agency should take every measure to ensure the safety and efficacy of prescription drugs under emergency use authorization. More
The maker of a drug shown to shorten recovery time for severely ill COVID-19 patients says it will charge $2,340 for a typical treatment course for people covered by government health programs in the United States and other developed countries. More
There’s another coronavirus. This one, causing horrific swelling in cats, even killing them. Gilead Pharmacueticals might have a drug that can cure this feline coronavirus. Yet, they’re not sharing that drug, possibly because they’re scared it might harm their chances with another drug: Remdesivir. You may have heard of it; it’s the supposed ‘gold standard’ of care for COVID-19. The story of Remdesivir (and of the black market cat drug sibling) reveals how pharmaceutical companies do their research, and the lengths they go to protect their profits. More
The case is the latest inquiry into pharmaceutical companies’ donations to patient assistance charities, which have been blamed for inflating the cost of drugs. More
Inmates at Angola prison in Louisiana told ProPublica of widespread illness, dysfunctional care and deadly neglect as the coronavirus outbreak hit. More
How much should remdesivir cost? This question puts two drug-value organizations at odds. More
The state's largest health care network says cost-saving measures will affect 50,000 workers across the company. More
U.S. health care prices are unregulated, opaque and unpredictable. When Congress required insurers to cover Covid-19 testing, a few providers decided to take advantage. More
During the pandemic, unions representing front-line medical staffers have stepped forward to advocate aggressively on behalf of their members. In some cases, they've won paid sick leave and hazard pay—and nonunion workers are watching. More
Visits from pharmaceutical sales reps haven't stopped during the pandemic--they've just moved online... More
Patients who were treated for the virus are largely supposed to be exempt from receiving large bills. One hospital erroneously sent one. More